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Abstract. We report the case of a 45-years-old man who came to Emergency Room of Polyclinic for a 
sudden onset of localized ecchymosis and widespread hematomas. He was subjected to blood count and 
first level investigations to assess the coagulation. Based on the results, second level investigations were 
performed. The endoscopy of the gastrointestinal tract with the histological examination has allowed the 
diagnosis of Crohn's disease. Vitamin K deficiency causes the formation of forms of vitamin K-dependent 
clotting factors that can not perform their pro-coagulant action. Consequently, patients present hemor-
rhagic manifestations. Clinical and laboratory features observed in this patient show that the deficiency of 
vitamin K-dependent coagulation factors may reveal a complex clinical condition such as a inflammatory 
bowel disease.
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Introduction
Vitamin K is an important coenzyme of hepatic 
γ-carboxylation of blood coagulation factors (FII, 
FVII, FIX, FX) and physiological inhibitors of co-
agulation (anticoagulant protein C and S) [1].
While an inherited enzyme deficiency involving vi-
tamin K metabolism is an extremely rare condition 
in adults, acquired vitamin K deficiency can occur 
in diseases that prevent the absorption of fats such 
as cystic fibrosis, celiac disease, and inflammatory 
bowel disease. It can also occur in patients undergo-
ing major surgery or in those treated with long-
term parenteral nutrition and broad-spectrum anti-
biotic therapy [2]. The classical clinical signs of 
vitamin K deficiency are skin and mucosal bleed-
ings. Characteristic laboratory data are a prolonged 
prothrombin time (PT) or activated partial throm-
boplastin time (aPTT), which are corrected by 
treatment with vitamin K. Crohn's Disease (CD) is 
classified as an inflammatory bowel disease (IBD). 
IBDs are a heterogeneous group of idiopathic, 
chronic, relapsing, inflammatory conditions pri-
marily affecting the gastrointestinal tract. CD is di-
agnosed based on clinical, radiological, endoscopic, 
and histological parameters. Patients usually suffer 
from symptoms such as abdominal pain and diar-
rhea, which may be complicated by intestinal fistu-
las, intramural abscesses, and bowel obstruction 
[3]. These patients have been reported to be at high 
risk of developing a deficiency of fat-soluble vita-
mins, including vitamin K [4,5].
Case report
We report the case of a 45-year-old Caucasian man pre-
sented to the Emergency Room (ER) of the University 
General Hospital Policlinico “P. Giaccone” in Palermo, 
Italy, because of a sudden onset of upper and lower limbs 
localized ecchymosis and widespread hematomas. No 
history of spontaneous or induced bleeding episode, nei-
ther antibiotics and non-steroidal anti-inflammatory 
drugs intake was reported. The patient presented arterial 
hypertension, which was treated with ACE inhibitors, 
and, in 2011, he underwent an inguinal hernia surgery 
without any complications. On admission, he under-
went to the following tests: complete blood cell count 
with morphological examination of peripheral blood 
smear, a kidney and hepatic function test, and first level 
coagulation assays (PT, aPTT and fibrinogen). No 
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Table 1. Results of first level coagulation assays performed in basal condition and after mixing test at room temperature 
(RT) and at 37°C. 
Test  Basal   MixTest at R.T.   MixTest at 37°C   Clinical reference  
           value
PT   No coagulation  12.7 sec.   13.0 sec.   11.0-13.0 sec.
     Ratio 1.10  Ratio 1.12  Ratio 0.8-1.2
     INR 1.09  INR 1.11  INR 0.9-1.3 
aPTT 57.7 sec   27.7 sec.   28.2 sec.   24-36 sec.
  Ratio 1.92  Ratio 0.92  Ratio 1.04  Ratio 0.8-1.2
FBN 331 mg/dL  -   -   150-450 mg/dL
Abbreviations: PT, prothrombin time; aPTT, activated partial thromboplastin time; FBN, fibrinogen; INR, international 
normalized ratio.
Table 2. Results of second level coagulation assays performed in basal condition, and after mixing test at room temperature 
(RT) and at 37°C.
Coagulation  Basal  MixTest at R.T.   MixTest at 37°C   Clinical reference
Factors          value
Factor II  17.8%  64.2%   65.8%   80-130%
Factor V  85.2%  -   -   60-140%
Factor VII 2.9%  75.8%   74.2%   50-130%
Factor VIII 124%  -   -   50-150%
Factor IX 11.4%  162.8%   158.4%   65-150%
Factor X  8.5%  93.3%   95.6%   77-130%
Factor XI 105%  -   -   65-150%
Factor XII 90.8%  -   -   50-150%
 
Physiological  Basal  MixTest at R.T.   MixTest at 37°C   Clinical reference  
coagulation         value   
inhibitors 
Antithrombin 94.6%  -   -   80-120%
Protein C 58%  80.4%   79.5%   70-140%
Protein S 64%  75.6%   76.6%   74-146%
Table 3. Fibrinolytic parameters
Fibrinolytic parameters        Clinical reference 
           value
D -dimer     125 ng/mL   10-250 ng/mL
FDP      < 10 µg/mL   < 10 µg/mL
Plasminogen     116 %    80-130%
α2-Antiplasmin     108 %    98-122%
Abbreviations: FDP, fibrin degradation products.
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alterations were reported except prolonged PT and 
aPTT as shown in Table 1. Based on these data, an ultra-
sonography examination of the upper abdomen and sec-
ond level coagulation assays including platelet function 
tests, dosages of coagulation factors [protein C and S, 
antithrombin, fibrinolytic parameters (d-dimer, FDP, 
plasminogen and α2-antiplasmin)], a mixing test, and a 
thromboelastogram (TEG) were performed. The ab-
dominal echography revealed no significant abnormali-
ties involving liver parenchyma, biliary tree, and the 
spleen. Platelets function testing (PFA100) showed no 
alteration of the haemostatic capacity of platelets both 
for collagen/ADP and collagen/epinephrine. Second 
level coagulation assays revealed decreased level of FII, 
FVII, FIX and FX, but normal level of FV, a decreased 
level of Protein C and S, normal Antithrombin levels, 
and fibrinolytic parameters in normal ranges (Tables 
2&3). All abnormal parameters were corrected after the 
mixing test, performed both at room temperature and at 
37°C. The TEG performed on citrated whole blood did 
not show any alteration, but it revealed an elongation of 
the “reaction time” not allowing clot formation when 
performed on platelet-poor plasma. A possible explana-
tion of the different behavior of the two TEG assays is 
that the “reaction time” is prolonged in the case of severe 
coagulation factors deficiency, low platelet count 
(<50000/mm3), and low fibrinogen levels (<100mg/dL). 
In cases like the one described, in order to detect a defect 
of plasmatic coagulation factors, it is appropriate to re-
move platelets from the sample so the “reaction time” 
will be elongated only in relation to the concentration of 
plasma coagulation factors. TEG assays performed after 
mixing the substance with normal plasma showed the 
complete normalization of the “reaction time”. Finally, a 
TEG performed after treatment with intramuscular ad-
ministration of vitamin K showed normal clot 
formations.
Based on the results of laboratory investigations, a diag-
nosis of combined deficiency of vitamin K-dependent 
coagulation factors was made. Accordingly, the patient 
was hospitalized, and he received treatment with vitamin 
K. Initially, oral vitamin K administration (10 mg) did 
not produce any correction of PT and aPTT values that 
were reached with parenteral administration.
In order to understand the etiology of vitamin K defi-
ciency, the following laboratory assays were performed: 
sieroprotein electrophoresis, albumina plasma levels, 
cholesterol, triglyceride, erythrocyte sedimentation rate 
(ESR), C Reactive Protein (CRP), faecal calprotectin, 
screening for autoimmunity, and a urine and stool ex-
amination. The results of these investigations showed an 
increase of ESR ,CRP, faecal calprotectin, and gamma-
globulin levels.
Endoscopic examinations of the gastro enteric tract (gas-
troscopy and colonoscopy with biopsy and histologic 
examination) led to the diagnosis of Crohn’s Diseases. 
Areas of chronic inflammation, comprising increased 
lamina propria plasma cells and lymphocytes, were as-
sociated with architectural distortion consisting of 
patchy, mild to severe, neutrophilic inflammation, in-
cluding neutrophilic cryptitis, crypt abscesses, and ero-
sions. The patient was assigned to the Gastroenterology 
Unit.
Discussion
Vitamin K is a fat-soluble vitamin with an essential 
role in the haemostatic process. Once vitamin K is 
absorbed from the gastrointestinal tract, it is trans-
ported to the liver via the hepatic portal vein where 
it acts as an essential cofactor for the conversion of 
peptide-bound glutamate to gamma-carboxy glu-
tamic acid (Gla) residues in a number of specialized 
Gla-containing proteins, including coagulation fac-
tors [6]. Patients suffering from vitamin K deficien-
cy present bleeding symptoms associated with pro-
longed PT and/or aPTT values. 
Crohn’s Disease is an idiopathic, chronic regional 
enteritis that can affect the gastrointestinal tract 
from mouth to anus, but it commonly involves the 
terminal ileum. Although the exact etiologies are 
uncertain, the pathogenesis of the disease is the re-
sult of three interacting elements: genetic suscepti-
bility factors, enteric micro flora abnormalities, and 
immune-mediated tissue injury [7]. Clinically, the 
disease has a chronic, indolent course, and it tends 
to relapse. Patients commonly present with symp-
toms related to ileocecal inflammation such as 
cramping, prolonged diarrhea, and low-grade fever 
[8].
We report the case of a patient who did not show 
any clinical common manifestations of the disease 
at presentation, but he suddenly experienced skin 
hemorrhagic manifestations due to an acquired 
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vitamin K deficiency. In an attempt to evaluate this 
deficit, we performed a laboratory test consistently 
with the clinical suspicion of a malabsorption re-
lated to vitamin K deficiency. Accordingly to The 
second European evidence-based Consensus on the di-
agnosis and management of Crohn's disease, the diag-
nosis of CD was made on the basis of endoscopic, 
histological and serological examinations [9]. The 
case described represents an atypical condition be-
cause vitamin K deficiency frequently occurs late in 
clinical history of CD and in association with al-
terations in bone metabolism [5,10]. In this pa-
tient, bone metabolism related markers and 25-hy-
droxyvitamin D resulted in the normal range, and 
no bone mineral density alterations were ever de-
tected by the dual-energy x-ray absorptiometry 
(DEXA) scan. Also the patient’s nutritional status, 
evaluated by serum pre-albumin and albumin, re-
vealed no alterations.
In conclusion, Crohn’s disease is a heterogeneous 
entity comprising a variety of complex phenotypes 
in terms of age of onset, disease location and disease 
behavior. In this case report, vitamin K deficiency 
occurs early and it is associated with bleeding 
events. No cases of bleeding as onset symptom of 
CD are described and the potential selective malab-
sorption of vitamin K has been never reported in 
literature. 
The underlying mechanisms of vitamin K malab-
sorption is still under investigation.
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